search
Back to results

The Influence of Resection Margin on the Recurrence of Early-stage Hepatocellular Carcinoma

Primary Purpose

Hepatocellular Carcinoma

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Wide resection margin >1cm
Narrow resection margin <1cm
Sponsored by
Eastern Hepatobiliary Surgery Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hepatocellular Carcinoma focused on measuring Wide resection margin, Recurrence, Early-stage hepatocellular carcinoma

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female patients > 18 years and <=70 years of age.
  • Diagnosed with HCC according to the criteria of American Association for the Study of Liver Diseases (AASLD).
  • Fulfill the Milan criteria.
  • High-risk of microvascular invasion (MVI).
  • Nomogram score >200.
  • Performance status score is 0-1 before the surgery.
  • Without or mild liver cirrhosis and the liver function is Child A class.
  • Without any other treatments such as TACE、PEI、PRFA before the surgery.

Exclusion Criteria:

  • Patients with macro tumor thrombus or extrahepatic metastasis.
  • Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction.
  • Subjects accepting other trial drugs or participating in other clinical trials.
  • Patients refuse to join our trial.
  • Female with pregnancy or during the lactation period.

Sites / Locations

  • Eastern hepatobilliary surgery hospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Wide resection margin >1cm

Narrow resection margin <1cm

Arm Description

Surgical removal of lesions choosing the method of wide resection margin >1cm

Surgical removal of lesions choosing the method of narrow resection margin <1cm

Outcomes

Primary Outcome Measures

Overall survival rates of each group

Secondary Outcome Measures

Occurrence rate of recurrence of each group

Full Information

First Posted
August 10, 2015
Last Updated
March 29, 2016
Sponsor
Eastern Hepatobiliary Surgery Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02525965
Brief Title
The Influence of Resection Margin on the Recurrence of Early-stage Hepatocellular Carcinoma
Official Title
The Influence of Resection Margin on the Recurrence of Early-stage Hepatocellular Carcinoma After Hepatectomy: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2016
Overall Recruitment Status
Unknown status
Study Start Date
August 2015 (undefined)
Primary Completion Date
December 2017 (Anticipated)
Study Completion Date
December 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Eastern Hepatobiliary Surgery Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Before the surgery, the investigators predict the risk of microvascular invasion (MVI) presence for the early-stage hepatocellular carcinoma according to the nomogram the investigators have created. Patients with a high risk of microvascular invasion were randomly chose to give the treatment of a wide resection margin, which establish an individualized anti-recurrence program based on the high-grade evidence-based medicine.
Detailed Description
Although liver resection is still the first line of treatment for hepatocellular carcinoma (HCC) presently, 5-year overall recurrence rates > 70%, the same with early-stage hepatocellular carcinoma, for some studies reported the rates > 40%. Recurrence is also the first cause of death in these patients, so recurrence is the most important factors affecting surgical results of HCC. For the precaution of cancer recurrence, there are no proven techniques for clinical reference at present. For now, there has been many controversies on the impact about the width of liver resection margin on curative effect. Poon has proven that there is no significant difference in recurrence rate between resection margin > 1cm and resection margin < 1cm. However, Shi et al published a randomized controlled trial: for patients with a solitary tumor, resection margin > 2cm can reduce the recurrence rate after hepatectomy. This is also the only randomized clinical trial study which proves increaseing resection margin will benefit the clinical results at present. A meta analysis consist of 18 studies proves that whether the resection margin has a relationship with a benefit clinical result still needs a further verification. On the other hand, because microvascular invasion (MVI) is the direct evidence of the micro metastasis in hepatocellular carcinoma, it will decrease recurrence rate for the patients with a high MVI risk, if the investigators increase the resection margin width during the surgery? Shanghai Eastern Hepatobiliary Surgery Hospital which the investigators affiliated with had ever conducted a retrospective analysis on consecutive 3263 patients with HCC hepatectomy, the results indicated that a wide resection margin(≥1cm)can benefit those patients with microvascular invasion , nevertheless, the benefit will not present if patients are without microvascular invasion. Further and better proofs still needs to approval this consequence, of course. In the past,another study of the ours, published online in the Journal of the American Medical Association Surgery, established a nomogram to predict the presence of microvascular invasion in the early-stage hepatocellular carcinoma, it will efficiently predict the occurrence of microvascular invasion in the hepatocellular carcinoma (HCC) fulfilled the Milan criteria. In consideration of the above basis, the investigators will implement a randomized controlled trial to certificate whether it could really reduce the recurrence rate after liver resection for participants with a high MVI risk during the surgery, if the method participants chose is a wide resection margin.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatocellular Carcinoma
Keywords
Wide resection margin, Recurrence, Early-stage hepatocellular carcinoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
194 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Wide resection margin >1cm
Arm Type
Experimental
Arm Description
Surgical removal of lesions choosing the method of wide resection margin >1cm
Arm Title
Narrow resection margin <1cm
Arm Type
Active Comparator
Arm Description
Surgical removal of lesions choosing the method of narrow resection margin <1cm
Intervention Type
Procedure
Intervention Name(s)
Wide resection margin >1cm
Intervention Description
Surgical removal of lesions choosing the method of wide resection margin >1cm
Intervention Type
Procedure
Intervention Name(s)
Narrow resection margin <1cm
Intervention Description
Surgical removal of lesions choosing the method of wide resection margin <1cm
Primary Outcome Measure Information:
Title
Overall survival rates of each group
Time Frame
3 years
Secondary Outcome Measure Information:
Title
Occurrence rate of recurrence of each group
Time Frame
3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patients > 18 years and <=70 years of age. Diagnosed with HCC according to the criteria of American Association for the Study of Liver Diseases (AASLD). Fulfill the Milan criteria. High-risk of microvascular invasion (MVI). Nomogram score >200. Performance status score is 0-1 before the surgery. Without or mild liver cirrhosis and the liver function is Child A class. Without any other treatments such as TACE、PEI、PRFA before the surgery. Exclusion Criteria: Patients with macro tumor thrombus or extrahepatic metastasis. Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction. Subjects accepting other trial drugs or participating in other clinical trials. Patients refuse to join our trial. Female with pregnancy or during the lactation period.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shen Feng, MD
Phone
0086-021-25070805
Email
shenfengdfgd@yahoo.com.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Wu Dong, MD
Phone
0086-021-25070765
Email
wuyuz@yahoo.com.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shen Feng, MD
Organizational Affiliation
Eastern Hepatobiliary Surgery Hospital, Second Military Medical University
Official's Role
Study Chair
Facility Information:
Facility Name
Eastern hepatobilliary surgery hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200438
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shen Feng, MD
Phone
0086-021-25070805
Email
shenfengdfgd@yahoo.com.cn
First Name & Middle Initial & Last Name & Degree
Wu Dong, MD
Phone
0086-021-25070765
Email
wuyuz@yahoo.com.cn
First Name & Middle Initial & Last Name & Degree
Shen Feng, MD

12. IPD Sharing Statement

Learn more about this trial

The Influence of Resection Margin on the Recurrence of Early-stage Hepatocellular Carcinoma

We'll reach out to this number within 24 hrs